Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis by Abolhassani, Hassan & Fatemeh, Kiaee
ORIGINAL ARTICLE
Fourth Update on the Iranian National Registry of Primary
Immunodeficiencies: Integration of Molecular Diagnosis
Hassan Abolhassani1,2,3 & Fatemeh Kiaee1,3 & Marzieh Tavakol4 & Zahra Chavoshzadeh5 & Seyed Alireza Mahdaviani6 &
Tooba Momen7 & Reza Yazdani1,3 & Gholamreza Azizi8 & Sima Habibi1,3 & Mohammad Gharagozlou9 &
Masoud Movahedi9 & Amir Ali Hamidieh10 & Nasrin Behniafard11 & Mohammamd Nabavi12 &
Mohammad Hassan Bemanian12 & Saba Arshi12 & Rasol Molatefi13 & Roya Sherkat14 & Afshin Shirkani15 & Reza Amin16 &
Soheila Aleyasin16 & Reza Faridhosseini17 & Farahzad Jabbari-Azad17 & Iraj Mohammadzadeh18 & Javad Ghaffari19 &
Alireza Shafiei20 & Arash Kalantari21 & Mahboubeh Mansouri22 & Mehrnaz Mesdaghi22 & Delara Babaie5 &
Hamid Ahanchian17 & Maryam Khoshkhui17 & Habib Soheili23 & Mohammad Hossein Eslamian24 & Taher Cheraghi25 &
Abbas Dabbaghzadeh18,43 & Mahmoud Tavassoli26 & Rasoul Nasiri Kalmarzi27 & Seyed Hamidreza Mortazavi28 &
Sara Kashef16 & Hossein Esmaeilzadeh16 & Javad Tafaroji29 & Abbas Khalili30 & Fariborz Zandieh20 &
Mahnaz Sadeghi-Shabestari31 & Sepideh Darougar6 & Fatemeh Behmanesh16 & Hedayat Akbari16 &
Mohammadreza Zandkarimi17 & Farhad Abolnezhadian32 & Abbas Fayezi32 & Mojgan Moghtaderi17 &
Akefeh Ahmadiafshar33 & Behzad Shakerian26 & Vahid Sajedi34 & Behrang Taghvaei35 & Mojgan Safari24 &
Marzieh Heidarzadeh36 & Babak Ghalebaghi25 & Seyed Mohammad Fathi37 & Behzad Darabi38 & Saeed Bazregari15 &
Nasrin Bazargan39 & Morteza Fallahpour12 & Alireza Khayatzadeh1 & Naser Javahertrash12 & Bahram Bashardoust6 &
Mohammadali Zamani40 & Azam Mohsenzadeh41 & Sarehsadat Ebrahimi9 & Samin Sharafian9 &
Ahmad Vosughimotlagh9 & Mitra Tafakoridelbari9 & Maziar Rahimi9 & Parisa Ashournia9 & Anahita Razaghian9 &
Arezou Rezaei1,3 & Setareh Mamishi42 & Nima Parvaneh1,3 & Nima Rezaei1,3 & Lennart Hammarström2 &
Asghar Aghamohammadi1,3
Received: 5 July 2018 /Accepted: 26 September 2018 /Published online: 9 October 2018
# Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract
Background The number of inherited diseases and the spectrum of clinical manifestations of primary immunodeficiency disor-
ders (PIDs) are ever-expanding. Molecular diagnosis using genomic approaches should be performed for all PID patients since it
provides a resource to improve the management and to estimate the prognosis of patients with these rare immune disorders.
Method The current update of Iranian PID registry (IPIDR) contains the clinical phenotype of newly registered patients
during last 5 years (2013–2018) and the result of molecular diagnosis in patients enrolled for targeted and next-
generation sequencing.
Results Considering the newly diagnosed patients (n = 1395), the total number of registered PID patients reached 3056 (1852
male and 1204 female) from 31 medical centers. The predominantly antibody deficiency was the most common subcategory of
PID (29.5%). The putative causative genetic defect was identified in 1014 patients (33.1%) and an autosomal recessive pattern
was found in 79.3% of these patients. Among the genetically different categories of PID patients, the diagnostic rate was highest
in defects in immune dysregulation and lowest in predominantly antibody deficiencies and mutations in theMEFV gene were the
most frequent genetic disorder in our cohort.
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Conclusions During a 20-year registration of Iranian PID patients, significant changes have been observed by increasing the
awareness of the medical community, national PID network establishment, improving therapeutic facilities, and recently by
inclusion of the molecular diagnosis. The current collective study of PID phenotypes and genotypes provides a major source
for ethnic surveillance, newborn screening, and genetic consultation for prenatal and preimplantation genetic diagnosis.
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Introduction
Primary immunodeficiency disorders (PIDs) comprise ap-
proximately 400 inherited disorders affecting the development
or the function of immune system components [1]. The overall
prevalence of PID has been estimated to be more than 1/600
individuals in Western countries [2–4]. However, this predic-
tion is likely to be an underestimation in countries with a high
rate of consanguineous marriages, since more than 70% of
known PID-associated genes have an autosomal recessive pat-
tern of inheritance [1]. PID patients may present with a broad
spectrum of clinical manifestations and immunological com-
plications mainly during childhood [5, 6]. Mutations in differ-
ent PID genes may result in similar presentations; however,
they may need also different management and therapeutic
measures. Wide variations in the geographical and ethnical
prevalence of PID have been reported by means of patients’
registry providing invaluable information for resource alloca-
tion and health policy making [3, 4].
Since the establishment of the Iranian Primary
Immunodeficiency Registry (IPIDR) in 1999, the diagnosis of
the patients was mainly based on clinical parameters, affecting
the process of definite diagnosis for targeted therapy and genetic
counseling. Before 2014, we had reported 1661 patients in three
consequential reports [7–9], but none of them included compre-
hensive information about the patient’s genetic background.
During the past 5 years, a growing number of clinical immunol-
ogists and recent advances inmolecular diagnostic methods have
led to an increase in the identification of genetic defects andmain
disease-causing gene mutations in the cohort, improving individ-
ualized therapeutic methods and the performance of prenatal
diagnosis [10]. This has also resulted in an earlier diagnosis, a
more precise definition of defects, reduced morbidity and mor-
tality rates, and better long-term outcomes [10, 11].
Of note, many of the novel PID gene defects, mainly in
autosomal recessive form, have been reported from the
Middle East region. Therefore, continuous update on these
registries has had a significant impact on our understanding
of the pathogenesis of PID and also the function of the im-
mune system [12, 13]. Here, we provide a recent update on
newly diagnosed Iranian patients with PIDs and integration of
molecular diagnostic outcomes based on the latest classifica-
tion of PIDs by the International Union of Immunological
Societies (IUIS) Expert Committee [1].
Materials and Methods
Iranian Primary Immunodeficiency Registry
This study was conducted as a cohort of patients, prospective-
ly enrolled in the IPIDR from the “National PID Network.”
The IPIDR is managed by the Research Centre for
Immunodeficiencies (Tehran, Iran) and its main aim is to pro-
vide epidemiological, clinical, and molecular data of PID in
Iran. By March 2013, 1661 PID patients from different prov-
inces of the country were registered in the IPIDR [7]. By the
latest estimation in 2016, Iran has a population of 79,926,270
citizens (with an average annual birth rate of 1,300,000) and
according to the age structure, 23.7% are less than 14 years
old. This study received approval from the Ethics Committee
of the Tehran University of Medical Science. Moreover, writ-
ten informed consent has been obtained from all patients, their
parents, or legal guardians.
Role of Participant Centers
The registry database is located in the Children’s Medical
Center (Tehran, Iran) which serves as a referral hospital for
suspected or diagnosed cases of PID. In addition, 31 medical
centers, affiliated to 26 medical science universities, collabo-
rated in the registry program from the major provinces of the
country to form the PID network (Fig. 1). All of the partici-
pating centers had access to national guidelines and necessary
laboratory equipment for clinical and immunological evalua-
tions. Subsequently, cases with suspected diagnosis were re-
ferred and re-evaluated in the Children’s Medical Center for a
definitive diagnosis.
Clinical and Immunologic Diagnoses
The clinical diagnosis of the PID patients was made according
to the criteria of the European Society for Immunodeficiencies
(ESID, https://esid.org/Working-Parties/Registry/Diagnosis-
criteria). A questionnaire surveyed the patients’ demographic
information, age of disease onset, age of diagnosis, family
history, detailed clinical history that included vaccination
history and associated adverse reactions, recurrent infections,
physical examination findings, laboratory data, and treatment
history. Secondary defects of the immune system, including
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those caused by human immunodeficiency virus (HIV), were
ruled out. Laboratory evaluations were performed in the study
group as indicated, including complete blood and differential
counts, serum protein profile and immunoglobulin (Ig) levels,
serum IgG subclass levels, isohemagglutinin titers, specific
antibody responses, disease-specific autoantibody measure-
ments, flow cytometric evaluation of lymphocyte subsets, ni-
tro blue tetrazolium dye/dihydrorhodamine test, granulocyte
function and chemotaxis tests, lymphocyte transformation and
T cell function tests, radiosensitivity, and measurement of
complement component levels and hemolytic complement ac-
tivity [14]. Microbiological, pathological, and imaging evalu-
ations were performed for clinical diagnosis when required. A
computerized database program (new registry section in http://
rcid.tums.ac.ir/) was implemented for data entry. After
reviewing the cases by the administrator of the system for
duplicated cases, patients with incomplete diagnostic criteria
were excluded. The online database was updated frequently
for approved patients and all follow-up data sent by the end of
the study period were included.
Genetic Analysis and Diagnoses
Genomic DNAwas extracted fromwhole blood, as previously
described [15]. For patients with classical clinical presenta-
tions suggestive of a specific PID, Sanger sequencing was
performed on the panel of most likely genes (Table S1).
Patients with thymic defects were examined by using fluores-
cent in situ hybridization (FISH) for 22q11.2 deletion and a
comparative genomic hybridization array. For patients in
whom Sanger sequencing failed or who had a clinical
presentation resembling several genetic defects, next-
generation sequencing (e.g., targeted gene sequencing [Table
S2] and whole exome sequencing) was performed to detect
single-nucleotide variants, insertions/deletions, and large de-
letions using a pipeline described previously [10, 11, 16].
Candidate variants were evaluated by the Combined
Annotation-Dependent Depletion (CADD) algorithm and an
individual gene cutoff given by using the mutation signifi-
cance cutoff (MSC) was considered for impact predictions
[17]. The Gene Damage Index (GDI) server and the Human
Gene Connectome (HGC) were used to make a combined
effects prediction [17]. The pathogenicity of all disease attrib-
utable gene variants was re-evaluated using the updated guide-
line for interpretation of molecular sequencing by the
American College of Medical Genetics and Genomics criteria
[18, 19], considering the allele frequency in the population
database, computational data, immunological data, familial
segregation and parental data (confirmatory Sanger sequenc-
ing for probands and their parents), and clinical phenotyping.
Statistical Analyses
After confirmation of their clinical and genetic diagnosis, pa-
tients were classified according to the IUIS updated classifi-
cation including nine categories of immunodeficiencies affect-
ing cellular and humoral immunity (non-syndromic combined
immunodeficiency or CID), combined immunodeficiencies
with associated or syndromic features (syndromic CID), pre-
dominantly antibody deficiencies (PAD), diseases of immune
dysregulation, congenital defects of phagocyte number or
function (phagocytosis disorders), autoinflammatory
Fig. 1 Schematic map of Iran
indicating the distribution of PID
network centers and cumulative
incidence of PID (per million) in
each province
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disorders, defects in intrinsic and innate immunity, comple-
ment deficiencies, and phenocopies of inborn errors of immu-
nity [1]. A commercially available software package (SPSS
Statistics 17.0.0; SPSS, Chicago, IL) was used for statistical
analysis and the one-sample Kolmogorov-Smirnov test was
applied to estimate whether data distribution was normal.
Parametric and nonparametric analyses were performed based
on the findings of this evaluation. Linear regression analysis
was performed to evaluate the chronological effect of time on
the different parameters. Kaplan-Meier curves and log-rank
tests were used to compare different survival estimates. A p
value of 0.05 or less was considered statistically significant.
Results
Newly Diagnosed Patients and Total Registry
Characteristics
A total number of 1395 PID patients (824 male and 571 fe-
male) were enrolled in the study in the time period between
March 2013 and March 2018. Due to an increased awareness
by physicians and improved diagnostic facilities [11], an esti-
mated incidence in this 5-year period was 0.21 cases per 1000
b i r t h s . Among the new ly d i agno s ed pa t i e n t s ,
autoinflammatory disorders were the most common group of
PID, affecting 438 cases (31.4%), followed by PAD in 310
patients (22.2%), syndromic CID in 256 cases (18.6%), de-
fects in innate immunity in 122 cases (8.7%), phagocytosis
disorders in 117 cases (8.4%), non-syndromic CID in 83 cases
(5.9%), diseases of immune dysregulation in 36 cases (2.6%),
and complement deficiencies in 33 cases (2.3%). The median
diagnostic delay was 10 months, ranging from 0 to 9.5 years.
Of the 1395 cases, a diagnosis was made in 934 patients
(66.9%) within 1 year from the onset of disease and within
2 years from the onset of disease in 1050 cases (75.2%).
Diagnostic delay was higher than 5 years in only 153 cases
(10.9%). The longest diagnostic delay was observed among
patients with complement deficiency (median, 10.3 years,
Table S3). Direct association between the age of the patients
at the onset of disease and diagnostic delay was observed
similar to our previous reports (r = 0.02, p = 0.001).
However, comparison of diagnostic delay in newly diagnosed
patients and old registered patients showed only a marginal
difference during last 5 years (p = 0.08).
Accounting the newly registered cases in IPIDR, epidemi-
ologic indexes of a total number of 3056 PID patients (1852
male and 1204 female) were evaluated. The cumulative inci-
dence of PID in Iran during the past 10 years was estimated to
be around 81 cases per 1,000,000 inhabitants. Figure 2 shows
the number of registered PID patients based on the IUIS-
classified group. Out of these 3056 PID patients, the majority
was diagnosed with PAD (903 cases, 29.5%, Table 1). Neither
cases with somatic mutations nor autoantibodies-mediated
phenocopies of inborn errors of immunity were diagnosed in
our cohort. Figure 1 shows the cumulative rate of clinical
diagnoses of PID in different regions of the country.
Demographic Data and Follow-up Outcome
The cohort that underwent registration was assigned to three
main ethnicities according to the reference population for the
Greater Middle East (GME, http://igm.ucsd.edu/gme/)
including Central Asia (80.3%) and Turkish (17.1%) and
Arabian (2.6%) Peninsulas. A family history of PID was
found in 641 cases (20.9%). Family history of recurrent
infections without a known diagnosis of PID was positive in
389 cases (12.7%). In 737 cases (24.1%), a positive family
history of death at an early age was documented. A history of
diagnosed cancer was reported in the family of 322 patients (10.
5%), and 208 individuals (6.8%) revealed a positive family
history of autoimmune disorders. Consanguineous marriage
was observed in the parents of 1837 cases (60.1%). There
was a significant difference between the consanguinity rates
of various types of PID, with the highest rate in patients with
immune dysregulation (72 cases, 94.7%) and the lowest rate in
patients with complement deficiencies (25 cases, 40.3%).
From 3056 patients, 1318 cases (43.0%) were confirmed to
be dead (827 male and 491 female) and 528 patients (17.2%)
could not be located during the last 6 months of the study
period. Beside the specific disorders with a frequency of less
than 10 cases, the mortality rate was highest in non-syndromic
CID (157 severe CID cases and 57 less profound CID) with a
mortality rate of 57.2% (214 out of 374 cases) and lost to
fo l low-up ra te of 9 .3% (35 out o f 374 cases ) .
Cardiopulmonary failure due to severe pneumonia and sepsis
was the main cause of death in 70.3% of the cases. Figure 3
compares the mortality rate in different PID categories pre-
senting the lowest survival rate in patients with a CID (mainly
due to severe CID) during the first 5 years of life (< 50%
survival, significantly different compared to complement de-
ficiencies [p = 0.02], immune dysregulations [p = 0.03], and
autoinflammatory diseases [p = 0.045]).
Genetic Diagnosis and Diagnostic Yield
According to the estimated prevalence of PIDs (1/600), the
expected prevalence of PIDs in Iran would be more than
130,000 individuals. To date, 3056 clinically diagnosed pa-
tients of PIDs (2.3% of expected patients) have been diag-
nosed, and a definite diagnosis, defined by mutation analysis,
was made in 1014 individuals (among 1457 evaluated pa-
tients, 69.5% diagnostic yield). As a result, 33.1% of the total
number of registered patients has been diagnosed at a molec-
ular level. Table 1 shows the frequency of patients in each
category of PID who are genetically diagnosed in Iran.
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Experimental data and the results of functional assays on 921
patients with genetic diagnosis have been published previous-
ly (Table 2). Of note, the cohort has had a great impact on
novel PID gene discovery including finding mutations in the
HAX1, G6PC3, ELA2, JAGN1, CARD9, IFNGR2, DOCK8,
STK4, LRBA, and CD70 genes. The majority of the patients
(n = 805, 79.3%) had an autosomal recessive disorder (75.9%
homozygous and 3.4% compound heterozygous). X-linked
disorders comprised 12.8% of the genetic diagnoses (n =
130) and 7.8% of patients had an autosomal dominant disease
(n = 79), where 76 mutations were de novo based on segrega-
tion analysis and Sanger sequencing of the parents (Fig. 4).
The probable prevalence of non-syndromic CID has been
reported to be 1/50,000 using both clinically diagnosed pa-
tients and newborn screening methods [20, 21]. Considering
the total population of Iran, the expected frequency of patients
would be 1600 individuals. Until now, there have been 374
patients with a clinical diagnosis of non-syndromic CID and
among them, 122 individuals have had a definite diagnosis
with known mutations. As a result, 23.3% of the expected
patients have been recognized and 32.4% of them have been
molecularly diagnosed. Based on the estimated prevalence of
syndromic CID (1/100,000) [20], 800 individuals would be
expected to be diagnosed in this PID group. Until now, 529
patients have been clinically diagnosed with syndromic CID
(66.1% of the expected frequency) and 117 patients (22.1%)
were diagnosed using mutation analysis. The estimated
prevalence of PAD is > 1/650 [20, 22], which results in an
expected frequency of more than 123,000 individuals consid-
ering the total population of Iran. It should be noted that ap-
proximately 70% of the estimated individuals are expected to
be asymptomatic and have no significant clinical complica-
tions as a cause of selective IgA deficiency or other specific
antibody defects. Only 903 PAD patients, 0.7% of the total
expected frequency, have been clinically diagnosed. Among
them, 111 patients (12.2%) have had a definite diagnosis by
molecular techniques.
Regarding diseases of immune dysregulation and their
expected prevalence (< 1/1,000,000 [20]), 95% of these pa-
tients have been registered by clinical diagnosis (76 of 80
expected patients) and 68 patients (89.4%) were genetically
diagnosed by identifying mutated genes. Since the country
is located in the eastern Mediterranean region, the probable
prevalence of autoinflammatory disorders is more than 1/
10,000 [20], and the expected frequency of patients with
these disorders would be approximately 8000 individuals.
To date, only 476 (5.9%) defined patients, mostly with a
clinical diagnosis of familial Mediterranean fever, have
been reported and 418 individuals (87.8%) have been defi-
nitely diagnosed by molecular techniques. Complement de-
ficiencies were expected with a prevalence of 1/50,000 [20];
however, only 62 patients (3.8% of the expected frequency)
and 2 patients (3.2% of registered patients) were diagnosed
clinically and genetically, respectively.
Table 1 Comparison of expected versus observed clinical diagnoses in different types of PID in Iran and the rate of molecular diagnosis in the
registered patients
Category Presumed
prevalence
Number of
expected cases
Clinically
diagnosed (N; %)
Genetically
diagnosed (N; %)
Immunodeficiencies affecting cellular and humoral immunity 1/50,000 1600 374 (23.3) 122 (32.4)
Combined immunodeficiencies with associated or syndromic features 1/100,000 800 529 (66.1) 117 (22.1)
Predominantly antibody deficiencies > 1/650 > 123,000* 903 (0.7) 111 (12.2)
Diseases of immune dysregulation < 1/1,000,000 80 76 (95.0) 68 (89.4)
Congenital defects of phagocyte number or function 1/250,000 320 507 (158.4) 117 (23.0)
Defects in intrinsic and innate immunity <1/1,000,000 80 134 (167.5) 59 (44.0)
Autoinflammatory disorders 1/10,000 8000 476 (5.9) 418 (87.8)
Complement deficiencies 1/50,000 1600 62 (3.8) 2 (3.2)
Total ≥ 1/600 ≥ 130,000 3056 (2.3) 1014 (33.1)
*It is estimated that 70% of patients with predominantly antibody deficiencies are asymptomatic
Fig. 2 Distribution of the
frequencies of PIDs according to
IUIS categories in 3065 Iranian
patients in the study
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Interestingly, the observed prevalence of phagocytosis dis-
orders and defects in innate immunity was higher than their
expected rate (1/250,000 and < 1/1,000,000, respectively
[20]). There have been 507 clinically diagnosed patients with
phagocytosis disorders (58% over than the estimated frequen-
cy) and 134 patients with defects in innate immunity (67%
over than the estimated frequency). Among these patients,
genetic mutations were identified in 117 (23.0%) from the
former and 59 (44.0%) from the latter disease groups. Table
2 summarizes the number of cases with different mutations
associated to PIDs reported in the cohort.
Discussion
Despite improved diagnostic techniques and molecular char-
acterization of different types of PID, the majority of patients
in worldwide registries are still without a definite genetic di-
agnosis. According to the findings of the updated analysis in
our registry and the estimated prevalence rates for different
forms of PID to date, only 2.3% of the expected (asymptom-
atic and symptomatic) patients have been diagnosed clinically,
and a molecular diagnosis has only been identified in 33.1%
of the registered cases. The rate of diagnosis at the molecular
level is comparable with well-known registries around the
world. Modell et al. at 2018 registered 102,097 patients from
86 countries spanning six continents, documented in the
Jeffrey Modell Foundation Network registry. The most
prevalent PID group was predominantly antibody deficien-
cies, accounting for almost half of the globally diagnosed
patients. The most prevalent symptomatic PID entity was
IgA deficiency, followed by common variable immunodefi-
ciency (CVID) and DiGeorge anomaly [23]. Although this
network was involved in several gene discoveries in the field
of PID, less than 35% of the reported patient had a confirmed
genetic defect [23].
The United States Immunodeficiency Network
(USIDNET) provides advanced scientific research in the field
of PID and epidemiologic indexes of patients registered in the
largest national database with 6584 participants. They also
reported PAD in 31.8% of household members with a specific
diagnosis for PID followed by chronic granulomatous disease
(8%) and thymic defect (DiGeorge anomaly, 7.8%). Genetic
diagnosis also was ascertained in 36.5% of patients mainly
with mutations in X-linked genes including BTK, CYBB, and
WAS (https://usidnet.org [3]). The ESID registry also contains
more than 20,000 patients where PAD represents the most
common category (56.8%), where CVID is the main PID
entity (21%). The PID genetic cause was known in
approximately 36% of all registered patients and mutations
in BTK, 22q11.2, and ATM were the most frequent recorded
defects in this multinational registry (https://esid.org/
Working-Parties/Registry/ESID-Database-Statistics [4]).
Analysis of genetic diagnosis data from 4530 patients in the
United Kingdom PID (UKPID) registry showed that 27%
have a recorded genetic mutation affecting mainly BTK,
Fig. 3 Kaplan-Meier curve
showing overall survival in the
3065 studied patients within the 8
categories of PIDs
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22q11.2, and CYBB (http://www.piduk.org [24]). Based on
the updated report of the Latin American Society for
Immunodeficiencies (LASID), this registry contains 6646
PID patients from 15 countries with an increased frequency
of antibody deficiency compared to other registries (62.9%).
Even though defects in BTK, 22q11.2, and CYBB are
estimated to be the main genetic diagnosis form in this
continent registry, the genetic composition remains unknown
(http://imunodeficiencia.unicamp.br:8080/estatistica mensal.
html [25]). Although PAD was the main clinical diagnosis in
our patients (29.5%) with a prominent increasing rate of
diagnosis compared to other forms of PID (Fig. 4), its propor-
tion is slightly lower than that inWestern countries, a phenom-
enon which is observed in many countries within the Middle
East region and Asia [26]. In contrast to all of the above-
mentioned studies, the three main causes of PID in the current
study were MEFV, BTK, and ATM, out of which two have an
autosomal recessive mode of inheritance, probably owing to
the high rate of parental consanguinity in the genetically di-
agnosed patients. Indeed, many defective genes with autoso-
mal respective inheritance that underlie PIDs were firstly de-
scribed in the patients originated from the Middle East area
with high rate of parental consanguinity. The DiGeorge anom-
aly is reported as one of the most common genetic defects in
PID patients in most Western countries; in contrast, only 13
patients were identified in our study (~ 8% versus 1.2% of
genetically diagnosed patients, respectively) [23]. The differ-
ence in our study may partly have been due to the obligatory
presence of immunologic profile alterations for consideration
of patients as PID. Moreover, a lack of referring patients with
prominent non-infectious features (e.g., congenital heart dis-
ease, hypocalcemia, facial abnormalities) for immunologic
Fig. 4 Trend of the frequency of
different PIDs (a) and the
inheritance pattern in patients
with definite molecular diagnosis
(b–c) in the IPIDR registry during
2002–2018 [7–9]
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evaluation may result in a lower rate of DiGeorge syndrome
discovery. Furthermore, the role of genetic ethnicity should be
considered as we observed among patients with X-linked
PIDs a similar pattern of dominancy of BTK mutations (84.
5% in our agammaglobulinemic patients compared to ~ 90%
in Western cohorts), while a less frequent proportion of muta-
tions in IL2RG (8.4% of our severe CID patients compared to
~ 60% in Western cohorts) and CYBB (29% of our chronic
granulomatous disease patients compared to ~ 70% in
Western cohorts) genes [3, 4].
The proportion of patients with a genetically definite
diagnosis varied between 89.4% in patients with immune
dysregulations and 3.2% in the cases with complement
deficiencies. This wide spectrum might be due to the nat-
ural history of the disease, unknown underlying genetic
defects, or complex disease pathogenesis including
multigenetic or epigenetic/non-genetic etiologies. Of note,
the patients with a lower genetic diagnostic yield also had
the lowest percentage of clinically diagnosed cases signi-
fying mild manifestations or non-infectious presentation.
Our recent studies using enhanced techniques of detection
of immunological abnormalities, mainly by targeted panel
sequencing and whole exome sequencing, have led to ear-
lier and more precise diagnosis of patients in both cate-
gories of antibody deficiency (improved from 7.8 to
12.2%) [10] and combined immunodeficiency (from 7.9
to 32%) [11]. A definite diagnosis of a PID allowed ge-
netic screening and counseling in more than half of our
patients’ cohort with the molecular diagnosis. Moreover,
carrier detection and preimplantation testing in conjunc-
tion with in vitro fertilization helped more than 20 fami-
lies to plan for their next child.
For the first time, we now report the comparative survival
analysis on the 20-year follow-up of different categories of
PID. Not surprisingly, CID patients had the highest mortality
rate compared to other registered patients [11]. Despite an
improvement in our national practice for therapeutic and pro-
phylactic antibiotics for infections and the most common
treatment options for PID patients including Ig replacement
therapy and immune modulators (e.g., interferon-gamma,
granulocyte colony-stimulating factor, and monoclonal anti-
bodies), hematopoietic stem cell transplantation (HSCT)
which is the mainstay of curative treatment in CID patients
is available only for a limited number of patients due to re-
strictions in expertise and financial resources. Of the patients
requiring HSCT, less than 100 patients (~ 3%) are under or
awaiting therapy. Although the resources for HSCT in Iran are
limited and no national program for newborn screening is
ongoing, genetic diagnoses are pivotal for confirming clinical
diagnoses, identifying new genetic carriers of CID genes, and
diagnosing of pre-symptomatic individuals.
In order to improve the coverage of genetic testing for PID
patients, several parameters should be considered including
clinical investigation of the probands, and cost of the test,
the probability of incidental findings, and the effects on rela-
tives of the index patient. Therefore, a stepwise clinical, im-
munological, and genetic approachmust be designed and used
for different entities of PID. Integration of medical and family
histories, findings of the physical examination and laboratory
data, and confirmatory evidence for pathogenicity of the can-
didate gene variants would be important for decision making
by clinical immunologists and immunogenetics experts. The
approximate number of diagnosed PID cases was reported to
be 7 per year in the 1980s, 30 per year in the 1990s, 58 per
year in 2000–2006, 104 per year in 2007–2013, and 279 per
year afterwards until the March of 2018 (Fig. 4). Although the
definite molecular diagnostic rate of PID in Iran is almost
similar to that in the developed countries, introduction of new-
born sequencing for PID, increasing the rate of clinical diag-
noses, providing more laboratory facilities and diagnostic mo-
dalities, and specialized immunogenetic centers for PID, in
addition to improvement of current national PID network,
should still be considered.
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